Mechanically speaking, in glioma, LHX9 was found to negatively interact with phosphoglycerate kinase 1 (PGK1), which dominates in the aerobic glycolysis pathway; while in gastric cancer, it mainly activates pyruvate kinase M2 (PKM2) to promote tumor progression. Here, PKM is linked to glioma.